Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation

International Journal of Hematology

Volumn 94, Issue 2, 2011, Pages 193-202

  Wakahashi, Kanako ^a   Yamamori, Motohiro ^b   Minagawa, Kentaro ^a   Ishii, Shinichi ^a   Nishikawa, Shinichirou ^a   Shimoyama, Manabu ^a   Kawano, Hiroki ^a   Kawano, Yuko ^a   Kawamori, Yuriko ^a   Sada, Akiko ^a   Matsui, Toshimitsu ^a   Katayama, Yoshio ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Drug monitoring; GVHD prophylaxis; MMF; Unrelated donor

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; ENGRAFTMENT; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MORNING DOSAGE; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; ORGAN DONOR; OVERALL SURVIVAL; PERSONALIZED MEDICINE; REDUCED INTENSITY CONDITIONING; RELAPSE; RELATIVE; SIDE EFFECT; VIRUS REACTIVATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MYCOPHENOLIC ACID; PHARMACOKINETICS; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052369329     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0888-6     Document Type: Article

References (25)

1. R Storb HJ Deeg M Pepe F Appelbaum C Anasetti P Beatty, et al. 1989 Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial Blood 73 1729 1734 2653461 1:STN:280:DyaL1M3ivFCjug%3D%3D (Pubitemid 19131924)
2. R Storb HJ Deeg J Whitehead F Appelbaum P Beatty W Bensinger, et al. 1986 Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia N Engl J Med 314 729 735 3513012 10.1056/NEJM198603203141201 1:STN:280: DyaL287ks1OltQ%3D%3D (Pubitemid 16124386)
3. HW Sollinger 1995 Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group Transplantation 60 225 232 7645033 10.1097/00007890-199508000-00003 1:CAS:528:DyaK2MXosVCiu78%3D
4. MB Maris BM Sandmaier BE Storer DG Maloney JA Shizuru E Agura, et al. 2006 Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing Biol Blood Marrow Transplant 12 454 465 16545729 10.1016/j.bbmt.2005.12.030 1:CAS:528:DC%2BD28XjslGnu7c%3D (Pubitemid 43380962)
5. CG Brunstein JN Barker DJ Weisdorf TE DeFor JS Miller BR Blazar, et al. 2007 Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease Blood 110 3064 3070 17569820 10.1182/blood-2007-04-067215 1:CAS:528:DC%2BD2sXht1Smu7zO (Pubitemid 350006962)
6. Y Nieto N Patton T Hawkins R Spearing SI Bearman RB Jones, et al. 2006 Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation Biol Blood Marrow Transplant 12 217 225 16443519 10.1016/j.bbmt.2005.10.012 1:CAS:528:DC%2BD28XitVGkurY%3D (Pubitemid 43138016)
7. Y Kawamori K Yakushijin A Okamura S Nishikawa K Minagawa M Shimoyama, et al. 2007 Successful engraftment in reduced-intensity cord blood transplantation (CBT) as a salvage therapy for graft failure after primary CBT in adults Transplantation 83 1281 1282 17496548 10.1097/01.tp.0000260635.19245.65 (Pubitemid 46743694)
8. P Jacobson J Rogosheske JN Barker K Green J Ng D Weisdorf, et al. 2005 Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation Clin Pharmacol Ther 78 486 500 16321615 10.1016/j.clpt.2005.08.009 1:CAS:528:DC%2BD2MXht1OltLnL (Pubitemid 41698903)
9. JA Perez-Simon R Martino D Caballero D Valcarcel N Rebollo R de la Camara, et al. 2008 Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis Biol Blood Marrow Transplant 14 664 671 18489992 10.1016/j.bbmt.2008.03.007 1:CAS:528:DC%2BD1cXnsFyqtL8%3D (Pubitemid 351664060)
10. B Bolwell R Sobecks B Pohlman S Andresen L Rybicki E Kuczkowski, et al. 2004 A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation Bone Marrow Transplant 34 621 625 15300236 10.1038/sj.bmt.1704647 1:CAS:528:DC%2BD2cXnsFejtbg%3D (Pubitemid 39341543)
11. I Osunkwo O Bessmertny L Harrison YK Cheung C Van de Ven G del Toro, et al. 2004 A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients Biol Blood Marrow Transplant 10 246 258 15077223 10.1016/j.bbmt.2003.11.005 1:CAS:528:DC%2BD2cXksVSrsbw%3D (Pubitemid 38456203)
12. RA Nash L Johnston P Parker JS McCune B Storer JT Slattery, et al. 2005 A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 11 495 505 15983549 10.1016/j.bbmt.2005.03.006 1:CAS:528:DC%2BD2MXnt1ymt7o%3D (Pubitemid 40862446)
13. L Giaccone JS McCune MB Maris TA Gooley BM Sandmaier JT Slattery, et al. 2005 Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation Blood 106 4381 4388 16144801 10.1182/blood-2005-06-2217 1:CAS:528:DC%2BD2MXhtlaltrjK (Pubitemid 41775952)
14. F Neumann T Graef C Tapprich M Vaupel U Steidl U Germing, et al. 2005 Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings Bone Marrow Transplant 35 1089 1093 15821769 10.1038/sj.bmt.1704956 1:CAS:528:DC%2BD2MXkt1Smtb4%3D (Pubitemid 40767198)
15. A Okamura M Yamamori M Shimoyama Y Kawano H Kawano Y Kawamori, et al. 2008 Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation Int J Hematol 88 104 110 18473127 10.1007/s12185-008-0093-4 1:CAS:528:DC%2BD1cXhtVOktb%2FI
16. A Okamura M Shimoyama S Ishii K Wakahashi N Asada H Kawano, et al. 2011 Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis Bone Marrow Transplant 46 148 149 20228852 10.1038/bmt.2010.59 1:STN:280: DC%2BC3M7gsVansg%3D%3D
17. JL Pinana D Valcarcel F Fernandez-Aviles R Martino M Rovira P Barba, et al. 2010 MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings Bone Marrow Transplant 45 1449 1456 20140024 10.1038/bmt.2009.362 1:CAS:528: DC%2BC3cXhtFaitbnO
18. S Nishikawa A Okamura M Yamamori K Minagawa Y Kawamori Y Kawano, et al. 2009 Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease Transplant Proc 41 3873 3876 19917404 10.1016/j.transproceed.2009.06.231 1:CAS:528:DC%2BD1MXhsVajsbjI
19. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows, et al. 1995 1994 consensus conference on acute GVHD grading Bone Marrow Transplant 15 825 828 7581076 1:STN:280:DyaK28%2Fot1Ojtw%3D%3D
20. HM Shulman KM Sullivan PL Weiden GB McDonald GE Striker GE Sale, et al. 1980 Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients Am J Med 69 204 217 6996481 10.1016/0002-9343(80) 90380-0 1:STN:280:DyaL3c3mtlSksg%3D%3D (Pubitemid 10036817)
21. T van Gelder Y Le Meur LM Shaw M Oellerich D DeNofrio C Holt, et al. 2006 Therapeutic drug monitoring of mycophenolate mofetil in transplantation Ther Drug Monit 28 145 154 16628123 10.1097/01.ftd.0000199358.80013.bd (Pubitemid 44314941)
22. ML MacMillan DJ Weisdorf CG Brunstein Q Cao TE DeFor MR Verneris, et al. 2009 Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors Blood 113 2410 2415 18997171 10.1182/blood-2008-07-163238 1:CAS:528:DC%2BD1MXjsFKhurY%3D
23. JP Klein JD Rizzo MJ Zhang N Keiding 2001 Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I. Unadjusted analysis Bone Marrow Transplant 28 909 915 11753543 10.1038/sj.bmt.1703260 1:STN:280:DC%2BD3MjgtFGlsg%3D%3D (Pubitemid 33130231)
24. I Haentzschel J Freiberg-Richter U Platzbecker A Kiani J Schetelig T Illmer, et al. 2008 Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation Bone Marrow Transplant 42 113 120 18362900 10.1038/bmt.2008.85 1:CAS:528: DC%2BD1cXovVClurs%3D
25. BC de Winter RA Mathot F Sombogaard I Neumann RM van Hest JK Doorduijn, et al. 2010 Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease Ther Drug Monit 32 606 614 20720518 10.1097/FTD. 0b013e3181efd715